| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -28,109,746 | -9,393,889 | -8,743,646 | -30,996,623 |
| Amortization of operating lease right-of-use asset | NaN | NaN | 62,038 | 152,212 |
| Stock-based compensation expense | 3,788,275 | 4,280,227 | 2,889,762 | 7,946,529 |
| Issuance of common stock for services | 0 | 107,510 | 26,600 | 0 |
| Issuance of common stock warrant | 0 | 68,597 | NaN | NaN |
| Amortization of in-process research and development | 1,720,312 | 573,438 | NaN | NaN |
| Depreciation | NaN | NaN | NaN | 0 |
| Amortization (accretion) of operating lease right-of-use asset | 40,659 | -16,483 | NaN | NaN |
| Deferred income tax expense | -231,210 | 264,240 | 264,240 | 792,720 |
| Accounts receivable, net of allowances | -2,970,056 | 4,049,111 | NaN | NaN |
| Inventory | 20,248 | 352,649 | 3,709,006 | 8,940,201 |
| Prepaid expenses | -178,405 | 2,139,797 | 1,451,034 | -1,386,824 |
| Accounts payable | -1,567,609 | -2,672,280 | 3,599,650 | 5,166,831 |
| Accrued expenses | 19,444,957 | 503,054 | -4,333,422 | 8,506,648 |
| Accrued compensation | 507,612 | -198,052 | -417,594 | 1,481,023 |
| Operating lease liability | -21,484 | 16,373 | -68,378 | -167,911 |
| Net cash used in operating activities | -1,300,021 | -13,008,822 | -11,880,790 | -14,671,948 |
| License fee payments | 600,000 | 4,400,000 | 5,750,000 | NaN |
| Net cash used in investing activities | -600,000 | -4,400,000 | -5,750,000 | NaN |
| Repayment of note payable | 1,000,000 | NaN | NaN | NaN |
| Proceeds from note payable and advance from employee | NaN | NaN | 0 | 1,300,000 |
| Deferred financing costs | 169,252 | NaN | NaN | NaN |
| Proceeds from sale of series a preferred stock | NaN | NaN | NaN | 100 |
| Repayment of advance from employee | NaN | NaN | 0 | 300,000 |
| Proceeds from exercise of citius oncology pre-funded warrants | 818 | NaN | NaN | NaN |
| Net proceeds from common stock offerings | -62,764 | 20,877,925 | 15,793,954 | 16,509,194 |
| Redemption of series a preferred stock | NaN | NaN | NaN | 100 |
| Net cash provided by financing activities | -1,231,198 | 20,877,925 | 15,793,954 | 17,509,194 |
| Net change in cash and cash equivalents | -3,131,219 | 3,469,103 | -1,836,836 | 2,837,246 |
| Cash and cash equivalents - beginning of period | 7,721,393 | 4,252,290 | 3,251,880 | NaN |
| Cash and cash equivalents - end of period | 4,590,174 | 7,721,393 | 4,252,290 | NaN |
Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc. (CTXR)